登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 一、虚增净利润误导市场 保利联合（维权）的违规行为最早在2024年初被揭露。根据证监会下发的行政处罚决定书显示，公司在 2019年至2021年期间，通过多种手段进行财务造假。其核心手段在于利用与客户签订的资金支付、还款 及资产抵押等协议作为幌子，将部分普通的应收账款错误地视为有担保的债权，从而人为调低了风险组 合划分。 责任编辑：韦子蓉 此外，由于账龄划分和计算的低级错误，导致公司大幅少计提坏账准备。这些行为直接造成了公司连续 三年的年报出现虚增净利润的情况，甚至导致2021年的盈亏性质发生了根本性逆转。这种刻意粉饰太平 的行为，严重误导了二级市场的估值逻辑。 二、投资者合法权益需捍卫 信息披露的真实性、准确性与完整性被视为资本市场的生命线。对于广大普通投资者而言，上市公司的 年报、财报是了解企业经营状况最权威、甚至是唯一的窗口。保利联合的财务造假行为 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我 （注：本案诉讼时效截止日期临近，请符合条件的投资者务必留意最后期限，及时行使权利！） 特别提醒 本案索赔诉讼时效预计将于2026年2月7日截止。时效届满后，投资者将丧失通过诉讼获得赔偿的权利。 请相关投资者务必抓紧时间，尽快进行索赔登记或咨询。 索赔所需基本材料 为启动索赔程序，投资者通常需要准备以下材料： 一、买卖ST慧辰（688500）股票的对账单原件 （1）对账单需加盖您所开户的证券公司营业部业务印章； 北京慧辰资道资讯股份有限公司（证券简称：*ST慧辰（688500）因信息披露违法违规行为，已于2023 年12月22日收到中国证券监督管理委员会下发的《行政处罚决定书》。目前，针对该事项的投资者索赔 诉讼已进入最后的收尾阶段。符合下述条件的受损投资者应及时采取法律行动，以维护自身合法权益。 索赔条件 根据相关法律法规及已披露信息，上海百悦律师事务 ...

索赔暂定条件（时间段二）： 凡于2022年4月23日至2024年4月30日期间买入贵州百灵（002424）股票，且在2024年4月30日之后卖出 或继续持有的亏损投资者。 登录新浪财经APP 搜索【信披】查看更多考评等级 根据相关法律意见及信息披露情况，贵州百灵企业集团制药股份有限公司（贵州百灵，002424）因涉嫌 信息披露违法违规，相关事项已引起监管关注。上海百悦律师事务所牛彬律师指出，符合条件的受损投 资者可依法准备索赔。 牛彬律师表示，根据相关情况，暂定符合以下任一时间段交易条件的亏损投资者（包括个人和机构）， 均有权参与索赔登记： 索赔暂定条件（时间段一）：（ST百灵维权入口） 凡于2020年4月30日至2024年4月30日期间买入贵州百灵（002424）股票，且在2024年4月30日之后卖出 或继续持有的亏损投资者。 二、投资者身份证正反面复印件； 三、证券公司营业部出具的证券账户查询单； 牛彬律师声明（牛彬律师专栏） 上述预登记条件仅供参考，不涉及任何投资决策和证券买卖建议。索赔条件将根据证监部门的进一步调 查结论进行调整，最终是否获赔及获赔金额需以人民法院的生效判决或调解为准。 （本文由上海百 ...

关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 一、监管下发预处罚 12月19日，福能东方（维权）因涉嫌通过虚构交易虚增近3600万元利润，收到了中国证券监督管理委员 会广东监管局开出的650万元罚单。一纸广东证监局的《行政处罚事先告知书》，揭开了福能东方连续 两年财务数据造假的真相。 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 公司披露的年度报告财务指标存在虚假记载，将被实施其他风险警示。明日（12月23日）复牌时，证券 简称将从"福能东方"变更为 "ST福能" 。 随着预处罚的送达，投资者维权也已拉开帷幕。上海沪紫律师事务所刘鹏律师团队正在征集受损投资者 中，前期已收到数百位投资者的索赔需求。 现符合于2021年4月14日-2024年12月6日（含当日）期间买入，并在2024年12月7日之后卖出或仍持 有而亏损的即可参与维权。（福能东方维权入口） 二、财务造假被坐实 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 2020年6 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) has issued a preliminary administrative penalty notice against Renfu Pharmaceutical Group Co., Ltd. for violations related to information disclosure, leading to potential legal actions from affected investors [1][6]. Summary by Sections Regulatory Actions - The CSRC's Hubei Regulatory Bureau has completed its investigation into Renfu Pharmaceutical and is set to impose administrative penalties due to violations of the Securities Law of the People's Republic of China [1][6]. Violations Identified - Key violations include failure to timely disclose significant litigation and arbitration matters, and inaccuracies in goodwill impairment testing for certain subsidiaries, resulting in misleading financial data in annual reports [6][7]. Investor Compensation - Affected investors who purchased Renfu Pharmaceutical stock between April 27, 2021, and October 22, 2024, and held or sold at a loss on October 22, 2024, may be eligible for compensation [2][7]. - Required documentation for claims includes original stock transaction statements, copies of the investor's ID, and a securities account confirmation from the brokerage [3][4][8].

登录新浪财经APP 搜索【信披】查看更多考评等级 受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年11月28日，天风证券（维权）股份有限公司发布《关于收到中国证券监督管理委员会立案告知书 的公告》。公告显示，公司于当日收到中国证监会下发的《立案告知书》（编号：证监立案字 【0052025018】号）。因涉嫌信息披露违法违规、违法提供融资，根据《中华人民共和国证券法》《中 华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 对此，已代理众多股票索赔案件的上海百悦律师事务所牛彬律师表示，根据相关法律法规，因上市公司 信息披露违法违规等行为给投资者造成损失的，受损投资者有权依法要求赔偿。 暂定索赔条件为：在2025年11月28日之前买入天风证券（601162）股票，并在2025年11月28日收盘 时仍持有或此后卖出该股票的亏损投资者（最终索赔条件以法院生效判决认定为准）。 索赔材料准备： 一、买卖天风证券（601162）股票的对 ...

Core Viewpoint - The case of ST Lifan highlights the severe consequences of systematic financial fraud in the A-share market, leading to administrative penalties and potential delisting due to significant violations of financial reporting standards [3][4]. Group 1: Company Overview - ST Lifan (300344.SZ) is facing administrative penalties and a potential delisting process due to long-term systematic financial fraud, as announced by the China Securities Regulatory Commission (CSRC) [3]. - The company has been found to have inflated revenues and costs by a total of 638 million yuan from 2021 to 2023, with specific annual figures indicating 280 million yuan in 2021, 312 million yuan in 2022, and 46 million yuan in 2023 [4][5]. Group 2: Regulatory Actions - The CSRC has proposed a fine of 10 million yuan against ST Lifan and a total of 30 million yuan in fines against ten responsible individuals, including a 10-year market ban for three senior executives [3][6]. - The company’s financial reports for 2021, 2022, and 2023 have been identified as containing false records, with the false revenue for 2021 and 2022 alone accounting for over 50% of the reported annual revenue [4][6]. Group 3: Fraud Mechanisms - ST Lifan employed various fraudulent methods, including agency business, financing trade, and fictitious trade, to inflate both revenue and costs [5]. - Key individuals, including the chairman and other executives, have been implicated for neglecting their duties and allowing fraudulent activities to occur [5][6]. Group 4: Market Impact - Following the announcement of the delisting risk, ST Lifan's stock price fell by 5.62% to 3.36 yuan on the day of the major delisting risk disclosure [4]. - The company is also facing additional legal challenges, including a contract dispute involving over 61 million yuan, which is linked to an ongoing criminal investigation [6]. Group 5: Investor Protection and Governance - The case underscores the need for stronger internal controls and independent oversight within companies to prevent financial misconduct [8]. - Recent legal cases in China have shown a shift towards collective investor protection mechanisms, indicating a growing trend in safeguarding investor rights against corporate fraud [7][8].

Core Viewpoint - The article highlights the severe consequences faced by ST Lifan due to long-term systematic financial fraud, leading to administrative penalties and the initiation of delisting procedures by the Shenzhen Stock Exchange [1][2]. Financial Misconduct - ST Lifan has inflated its revenue by 638 million yuan and costs by 628 million yuan from 2021 to 2023 through various fraudulent activities [2]. - The inflated figures for each year are as follows: 2021 saw revenue and costs inflated by 280 million yuan and 277 million yuan respectively; 2022 saw 312 million yuan and 305 million yuan; and 2023 saw 46 million yuan and 45 million yuan [2]. - The company’s financial reports for 2021 and 2022 contained false records amounting to 591.58 million yuan, which constituted 50.91% of the total reported revenue for those years [2]. Regulatory Actions - The China Securities Regulatory Commission (CSRC) has proposed a fine of 10 million yuan against ST Lifan and a total of 30 million yuan against 10 responsible individuals, including a 10-year market ban for three senior executives [1][3]. - The Shenzhen Stock Exchange will initiate delisting procedures due to the company’s significant violations [1][2]. Corporate Governance Issues - The fraudulent activities were facilitated by key executives, including the chairman and general manager, who neglected their duties and allowed the misconduct to occur [3]. - The company’s internal controls and oversight mechanisms were ineffective, as evidenced by the systemic fraud despite multiple individuals signing declarations of accuracy and completeness [4]. Legal and Market Implications - The company faces additional legal challenges, including a contract dispute linked to a criminal investigation, which may impact its future profitability [4]. - A significant shareholder's stock will undergo a second judicial auction, although it is noted that this will not change the company's control [4]. Investor Protection and Market Confidence - Recent cases in China indicate a shift towards systematic investor protection mechanisms, with collective redress becoming more prevalent [5]. - However, the article emphasizes that post-fraud compensation cannot fully restore market confidence or mitigate the liquidity loss from delisting [6]. - There is a call for stronger governance measures to ensure compliance and accountability among executives, as well as enhanced audit responsibilities for accounting firms [6].

Core Viewpoint - The investigation by the China Securities Regulatory Commission (CSRC) into Ba Yi Steel for suspected information disclosure violations has led to a significant drop in the company's stock price, reflecting market concerns over its financial stability and governance [2][3]. Group 1: Investigation Impact - Ba Yi Steel's stock opened at the daily limit down following the announcement of the CSRC's investigation, indicating severe market reaction [3]. - The company and its controlling shareholder received a notice from the CSRC regarding the investigation, which has raised concerns among investors about potential risks [3]. - Historical data suggests that once a company is under investigation, short-term stock price volatility is likely, with long-term effects depending on the investigation's outcome and the company's response [3]. Group 2: Financial Performance - Ba Yi Steel has reported continuous losses over the past three years, with a cumulative net loss exceeding 4 billion yuan from 2022 to 2024 [4]. - In the first three quarters of the current year, the company managed to turn a profit with a net profit of 125 million yuan, but its overall revenue remains low compared to peers, ranking 17th out of 17 in its industry with a revenue of 14.617 billion yuan [4]. - The Shanghai Stock Exchange has previously inquired about fluctuations in the company's advance payments, suggesting potential issues related to related-party transactions, which may be linked to the current investigation [4]. Group 3: Investor Rights and Compensation - Following the investigation, investor losses have become a focal point, with the number of Ba Yi Steel shareholders reaching 88,500, a 26.38% increase, while the average shareholding per investor has decreased by 20.87% [6]. - Investors who purchased Ba Yi Steel shares before November 7, 2025, and sold or held them after November 8, 2025, at a loss are eligible to participate in collective litigation for compensation [6]. - The establishment of a compensation channel by investment media indicates a growing awareness among investors regarding their rights and the importance of market transparency [6].

Core Viewpoint - The delisting of Nuohui Health from the Hong Kong Stock Exchange marks a significant event, but it does not signify the end of the company, as it is undergoing restructuring and legal actions related to investor rights [1][2]. Company Developments - Nuohui Health has significantly reduced its sales team while retaining its medical department, possibly to renew existing certifications and apply for new ones [2]. - The company's HPV screening product "Gongzhengqing" has been rejected by the drug regulatory authority, while the renewal process for its "early screening first certificate" is ongoing [2]. Investor Rights and Legal Actions - Over 4,000 individual investors have formed a rights protection community, led by Zhu Jiang, to pursue legal action in both mainland China and Hong Kong to recover losses [3][21]. - The upcoming hearing for a winding-up petition in the Cayman Islands court is a critical step in the forced delisting process, which could lead to significant financial losses for individual investors [3][17]. Legal Framework and Challenges - The ideal path for investor rights protection involves prior administrative investigations confirming financial fraud, which is not currently available in the Nuohui case [4][6]. - The lack of official conclusions from regulatory bodies complicates the legal recourse for investors compared to similar cases in mainland China [6][9]. - The complexity of pursuing legal action across different jurisdictions (Hong Kong and mainland China) introduces uncertainties regarding evidence acceptance and jurisdictional authority [19][20]. Financial Accountability - In cases of large-scale financial fraud, accountability typically falls on those who executed the actions, but the frequent turnover of company personnel raises questions about long-term responsibility [13][14]. - Auditors may face liability if they fail to detect fraud despite following proper auditing procedures, but proving negligence can be challenging [14][15]. Market Context - The delisting of Nuohui Health highlights broader concerns for mainland investors in Hong Kong stocks, especially as more investors enter the market [21].